The Comprehensive Cancer Center of Wake Forest University (CCCWFU) is requesting a renewal of its Cancer Center Support Grant from the National Cancer Institute for Years 25 through 29. In the past 3 years, the CCCWFU has experienced consistent growth and achievement: the peer reviewed support base increased from approximately $10 million to over $16 million, substantial new facilities and capital equipment have been added to the Center, the programmatic structure developed three years ago has matured, and all senior leadership positions have been filled. The Cancer Center continues an outstanding record of clinical trials participation and translational research, community-based research in early detection and prevention, and basic science innovation. The CCCWFU has recruited faculty to enhance its cancer focus, has developed novel molecular approaches to cancer diagnosis and therapy, and has a clear or accessible organization with carefully enumerated priorities. Our medical center has maintained its outstanding record of commitment to the Cancer Center. Seven Programs constitute the scientific organization of our Cancer Center: Clinical Trials Program and Breast Program (Clinical Research Division), Early Detection and Medical Outcomes Program and Epidemiology and Prevention Program (Cancer Control Division), and Molecular Diagnosis and Therapy Program, Signaling Program, and DNA Damage and Cellular Defence Program (Basic Science Division).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-26
Application #
2871643
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1976-03-01
Project End
2001-01-31
Budget Start
1999-02-01
Budget End
2001-01-31
Support Year
26
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Su, Weijun; Hong, Lixin; Xu, Xin et al. (2018) miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene 37:5618-5632
Miller Jr, David P; Denizard-Thompson, Nancy; Weaver, Kathryn E et al. (2018) Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Ann Intern Med 168:550-557
Bonin, Keith; Smelser, Amanda; Moreno, Naike Salvador et al. (2018) Structured illumination to spatially map chromatin motions. J Biomed Opt 23:1-8
Rimkus, Tadas K; Carpenter, Richard L; Sirkisoon, Sherona et al. (2018) Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res 78:2589-2600
Maggiore, Ronald J; Callahan, Kathryn E; Tooze, Janet A et al. (2018) Geriatrics fellowship training and the role of geriatricians in older adult cancer care: A survey of geriatrics fellowship directors. Gerontol Geriatr Educ 39:170-182
Rogers, LeAnn C; Davis, Ryan R; Said, Naveen et al. (2018) Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy. Redox Biol 15:380-386
Faig, Jennifer; Haughton, Michael; Taylor, Richard C et al. (2018) Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy. Am J Clin Oncol 41:432-440
Melvin, Ryan L; Xiao, Jiajie; Godwin, Ryan C et al. (2018) Visualizing correlated motion with HDBSCAN clustering. Protein Sci 27:62-75
Swanner, Jessica; Singh, Ravi (2018) Synthesis, Purification, Characterization, and Imaging of Cy3-Functionalized Fluorescent Silver Nanoparticles in 2D and 3D Tumor Models. Methods Mol Biol 1790:209-218
Nelson, Kimberly J; Perkins, Arden; Van Swearingen, Amanda E D et al. (2018) Experimentally Dissecting the Origins of Peroxiredoxin Catalysis. Antioxid Redox Signal 28:521-536

Showing the most recent 10 out of 548 publications